Abstract
In general, detection of peritoneal carcinomatosis (PC) occurs at the late stage when there is no treatment option. In the present study, we designed novel drug delivery systems that are functionalized with anti-CD133 antibodies. The C1, C2 and C3 complexes with cisplatin were introduced into nanotubes, either physically or chemically. The complexes were reacted with anti-CD133 antibody to form the labeled product of A0-o-CX-chem-CD133. Cytotoxicity screening of all the complexes was performed on CHO cells. Data showed that both C2 and C3 Pt-complexes are more cytotoxic than C1. Flow-cytometry analysis showed that nanotubes conjugated to CD133 antibody have the ability to target cells expressing the CD133 antigen which is responsible for the emergence of resistance to chemotherapy and disease recurrence. The shortest survival rate was observed in the control mice group (K3) where no hyperthermic intraperitoneal chemotherapy procedures were used. On the other hand, the longest median survival rate was observed in the group treated with A0-o-C1-chem-CD133. In summary, we designed a novel drug delivery system based on carbon nanotubes loaded with Pt-prodrugs and functionalized with anti-CD133 antibodies. Our data demonstrates the effectiveness of the new drug delivery system and provides a novel therapeutic modality in the treatment of melanoma.
Highlights
Peritoneal carcinomatosis (PC) presents a significant challenge within current surgical oncology
This study evaluated the potential of selected nanovehicles in modified targeted hyperthermic intraperitoneal chemotherapy without perfusion as a novel chemotherapeutic strategy for peritoneal carcinomatosis
One important issue is how oncologic outcomes can be enhanced through the modification of current clinical procedures like hyperthermic intraperitoneal chemotherapy (HIPEC) for patients suffering from peritoneal carcinomatosis (PC) [48]
Summary
Peritoneal carcinomatosis (PC) presents a significant challenge within current surgical oncology. PC refers to a variety of organ-based malignancies in the peritoneal cavity resulting from uncontrolled and rapidly progressing metastatic processes [1,2,3]. PC has a very poor prognosis and it is invariably terminal [4,5,6,7]. The combination of palliative cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are promising and significantly improve the patient’s quality of life. These combinations are characterized by a high in-hospital mortality rate and short periods of survival [89]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have